We have read with great interest the study by Liang et al.addressing the role of radical resection combined with intestinal autotransplantation for locally advanced pancreatic cancer after neoadjuvant therapy(1).The s...We have read with great interest the study by Liang et al.addressing the role of radical resection combined with intestinal autotransplantation for locally advanced pancreatic cancer after neoadjuvant therapy(1).The study may attract the attention of the pancreato-biliary oncological and surgical community.展开更多
I’ve read with great interest the paper of Machairas et al.(1)which is of great interest for the oncological and surgical community.Pancreatic adenocarcinoma(PDAC)is still considered a malignancy with an extremely po...I’ve read with great interest the paper of Machairas et al.(1)which is of great interest for the oncological and surgical community.Pancreatic adenocarcinoma(PDAC)is still considered a malignancy with an extremely poor prognosis,being currently the 4th cause of death for cancer and,according to the Global Cancer Statistics in the next decade,it may ascend up to the third cause of death(2).During the last decades,there have been great efforts to improve survival of potentially resectable pancreatic cancer through several improvements.Firstly,the selection of patients:newer preoperative studies have been able to select those patients that might really benefit from resection.Secondly,the surgical procedure itself improved its outcome:proper mesopancreatic dissection and lymphadenectomy,superior mesenteric artery approach and vascular resection have been able to enhance the R0 resection rate with acceptable morbidity(3).Finally,newer chemotherapies regimens have been introduced,as well,with relevant survival improvement(4).展开更多
文摘We have read with great interest the study by Liang et al.addressing the role of radical resection combined with intestinal autotransplantation for locally advanced pancreatic cancer after neoadjuvant therapy(1).The study may attract the attention of the pancreato-biliary oncological and surgical community.
文摘I’ve read with great interest the paper of Machairas et al.(1)which is of great interest for the oncological and surgical community.Pancreatic adenocarcinoma(PDAC)is still considered a malignancy with an extremely poor prognosis,being currently the 4th cause of death for cancer and,according to the Global Cancer Statistics in the next decade,it may ascend up to the third cause of death(2).During the last decades,there have been great efforts to improve survival of potentially resectable pancreatic cancer through several improvements.Firstly,the selection of patients:newer preoperative studies have been able to select those patients that might really benefit from resection.Secondly,the surgical procedure itself improved its outcome:proper mesopancreatic dissection and lymphadenectomy,superior mesenteric artery approach and vascular resection have been able to enhance the R0 resection rate with acceptable morbidity(3).Finally,newer chemotherapies regimens have been introduced,as well,with relevant survival improvement(4).
